Answers are grounded in this paper and cite their sources.
Effective antitumor immunity depends on immune priming within tumor-draining lymph nodes (TDLNs), yet therapeutic strategies targeting these immune-organizing sites remain limited. Here, we leveraged single-cell profiling of human colorectal cancer TDLNs to guide the design of a biomimetic nanoadjuvant for TDLN-targeted cancer immunotherapy. Single-cell and bulk transcriptomic analyses identified a LAMP3⁺ dendritic cell (DC) state associated with enhanced antigen presentation, costimulation, innate immune sensing, and antigen-experienced CD8⁺ T cell responses. Inspired by this human immune state, we engineered a DC membrane coated iridium-manganese oxide nanoadjuvant (IMOD NAs) loaded with ovalbumin (OVA) that integrates biomimetic recognition with coordinated redox and innate immune regulation. The DC membrane camouflage enhanced TDLN targeting, DC interaction and OVA delivery, whereas the IrMn oxide core simultaneously activated ROS-NF-κB and Mn²⁺-dependent STING signaling, thereby promoting DC maturation, migration, and antigen presentation. Remarkably, IMOD NAs reprogrammed TDLNs toward an immune-competent state, enhanced cytotoxic CD8⁺ T cell priming, and reduced regulatory T cell accumulation. In vivo, IMOD NAs suppressed tumor growth and markedly enhanced the therapeutic efficacy of PD-L1 blockade. Taken together, this study establishes a human immune state guided strategy for biomimetic nanoadjuvant design and demonstrates TDLN reprogramming as a complementary approach to improve cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: